Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
Mahender Kumar Medisetty,
Atul Patel,
Sanjay Pujari
Affiliations
Mahender Kumar Medisetty
Corresponding author.; Apollo Institute of Medical Science and Research, Apollo Health Campus, Hyderabad, India
Atul Patel
Department of Infectious Disease, Sterling Hospital, Ahmedabad, India
